Avonex Labeling Change Will Not Affect Sales, Accredo CFO Says
This article was originally published in The Pink Sheet Daily
Executive Summary
A warning on hepatic injury recently added to Biogen Idec's Avonex labeling "will have little, if any, impact on" sales, Accredo CFO Kimbrough says. The specialty pharmacy distributor handles 40% of U.S. Avonex sales.
You may also be interested in...
Biogen Idec Adds Liver Warning To Multiple Sclerosis Therapy Avonex
Interferon beta product joins Serono/Pfizer's Rebif with warning reflecting postmarketing experiences. Berlex' Betaseron does not have a warning but recommends testing. Coming on the heels of the Tysabri withdrawal, the labeling change is the second recent setback for Biogen Idec's multiple sclerosis franchise.
Medco Creates Largest U.S. Specialty Pharmacy Through Accredo Acquisition
The companies' combined specialty drug sales were about $4.3 bil. in 2004. The acquisition puts Medco in a position to take a large share of Medicare Part B drug business in addition to its stake in the Part D outpatient drug benefit.
Italy Leads European Push Into Conditional Reimbursement
Italy claims to have pushed farther into managed entry agreements than other European countries with strong clawback provisions on new drugs – particularly cancer drugs – if they don't work as well as their manufacturers claim. The financial clawbacks are supported by extensive outcome data collection across the country's twenty regions.